{
    "nct_id": "NCT03879629",
    "official_title": "TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial",
    "inclusion_criteria": "* â‰¥18 years of age,\n* new or locally recurrent diagnosis of HER2+ breast cancer that will be treated with curative intent\n* planned HER2-directed (any therapy targeting HER2 signaling including Trastuzumab +/- pertuzumab or trastuzumab-emtansine (T-DM1) Nerantinib and lapatinib will not be considered. \"HER2-directed therapy\" or \"anti-HER-2\".\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* history of HF of any class and type, or diagnosis of cardiomyopathy in the past,\n* LVEF <50% at screening,\n* intolerance to beta-blocker,\n* baseline use of any beta-blocker for coronary artery disease including myocardial infarction\n* current ACE inhibitor or ARB therapy for hypertension in the presence of diabetes and/or for chronic kidney disease/proteinuria,\n* on active therapy with amiodarone, sotalol, or any other antiarrhythmic\n* Diagnosis of asthma with current daily use of anti-asthmatic therapy\n* heart rate < 50 BPM at screening (average of 3 most recent readings)\n* history of or current sick sinus syndrome,\n* AV block grade II or higher (unless patient has a permanent pacemaker) at screening,\n* systolic blood pressure < 90 mmHg at screening (average of 3 most recent readings)\n* severe hepatic dysfunction, as defined by NCI ODWG (total bilirubin >3x ULN, any AST elevation) or Child Pugh C class\n* pregnancy\n* Metastatic breast cancer (distant metastases)\n* Active systemic treatment for non-breast cancer",
    "miscellaneous_criteria": ""
}